"Radiopharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
| Descriptor ID |
D019275
|
| MeSH Number(s) |
D27.505.259.843 D27.505.519.871 D27.720.470.410.650
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Radiopharmaceuticals".
Below are MeSH descriptors whose meaning is more specific than "Radiopharmaceuticals".
This graph shows the total number of publications written about "Radiopharmaceuticals" by people in this website by year, and whether "Radiopharmaceuticals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 5 | 5 |
| 2003 | 3 | 2 | 5 |
| 2004 | 0 | 5 | 5 |
| 2005 | 1 | 3 | 4 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 3 | 3 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 1 | 5 | 6 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 6 | 7 |
| 2014 | 3 | 13 | 16 |
| 2015 | 4 | 5 | 9 |
| 2016 | 2 | 3 | 5 |
| 2017 | 3 | 7 | 10 |
| 2018 | 3 | 2 | 5 |
| 2019 | 4 | 3 | 7 |
| 2020 | 1 | 5 | 6 |
| 2021 | 1 | 7 | 8 |
| 2022 | 1 | 6 | 7 |
| 2023 | 1 | 3 | 4 |
| 2024 | 4 | 2 | 6 |
| 2025 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Radiopharmaceuticals" by people in Profiles.
-
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). Future Oncol. 2025 Nov; 21(26):3377-3384.
-
2024 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. J Nucl Med Technol. 2025 Sep 05; 53(3):193-197.
-
Evaluation of coadministration schedules of rA1M for kidney protection after administration of 177Lu-octreotide. Radiat Prot Dosimetry. 2025 Aug 26; 201(13-14):995-1005.
-
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). Breast. 2025 Jun; 81:104432.
-
Relationships between hypometabolism and both ?-amyloid and tau PET in corticobasal syndrome. Alzheimers Dement. 2025 03; 21(3):e70018.
-
Consensus Radiation Treatment Planning Guidelines Using (68)Ga-DOTATATE PET/CT For Resected Meningiomas. Int J Radiat Oncol Biol Phys. 2025 May 01; 122(1):150-158.
-
Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties of 177Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. Mol Pharm. 2024 08 05; 21(8):4004-4011.
-
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Dec 01; 120(5):1332-1343.
-
18F-FDG PET/CT and radiolabeled leukocyte SPECT/CT imaging for the evaluation of cardiovascular infection in the multimodality context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations from ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. Heart Rhythm. 2024 05; 21(5):e1-e29.
-
18F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations From ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. JACC Cardiovasc Imaging. 2024 Jun; 17(6):669-701.